Seth Hartung
Critical Care Medicine · Everett, WANPI 1043337751
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by AstraZeneca at 32.9% of the total. Reporting peaked in 2019 at $152 and has fallen 88.8% since, to $17 in 2025.
Across 16 payments — averaging $20.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$108
- Genentech, Inc.$97
- GSK$43
- Sanofi$27
- Amgen$23
- Inari Medical, Inc.$17
- plus $12 from 1 others
What the payments were for
- Food & beverage$327100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 6 | $108 |
| Genentech, Inc. | 2 | $97 |
| GSK | 3 | $43 |
| Sanofi | 2 | $27 |
| Amgen | 1 | $23 |
| Inari Medical, Inc. | 1 | $17 |
| Novartis | 1 | $12 |
How this compares
$327 in reported general payments places this provider in the 65th percentile of 115 critical care medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 43 | $555,100 |
| GlassiaAlpha-1-Proteinase Inhibitor | 13 | $109,944 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 138 | $101,822 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 91 | $52,142 |
| Dupixent PenDupilumab | 12 | $45,390 |
| Spiriva HandihalerTiotropium Bromide | 51 | $39,479 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 79 | $37,640 |
| Spiriva RespimatTiotropium Bromide | 51 | $27,171 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 200 | $24,232 |
| Breo ElliptaFluticasone/Vilanterol | 47 | $19,507 |
| Incruse ElliptaUmeclidinium Bromide | 49 | $19,356 |
| SymbicortBudesonide/Formoterol Fumarate | 50 | $16,405 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 29 | $15,681 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $14,263 |
| Advair HfaFluticasone Propion/Salmeterol | 23 | $11,545 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $43 | $181,995330 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $108 | $30,66868 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 115 critical care medicine providers in Washington.
Other critical care medicine in Everett
- Niket NathaniEverett$1K
- Anita TsenEverett$677
- Shoaib FakhriEverett$403
- Claude ZeifmanEverett$174
- Phillip GregoireEverett$128
- Vinay GuptaSeattle$185K
- Sara NikravanSeattle$106K
- Michael SouterSeattle$20K
- Ravinder ShergillVancouver$16K
- Oliver McElvaneySeattle$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.